Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Fangyuan Pharma Plans Trials of New-to-China Antibiotic

publication date: Jul 12, 2016
Changzhou Fangyuan Pharma of Jiangsu Province has completed pre-clinical development work on a difficult-to-produce antibiotic that is effective against methicillin-resistant and gram-negative infections. Arbekacin sulfite was first approved in Japan in 1990, but has now become a generic. Fangyuan plans to file to start clinical trials of arbekacin sulfite in China. Fangyuan said it was helped by the Chinese Academy of Engineering Wang Guangji Academic Workstation, which was set up on Fungyuan's premises. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital